Serial No.: 10/748,117

RECEIVED
CENTRAL FAX CENTER
APR 16 2007

REMARKS

Claims 1-85 are pending in the application.

Support of the amendment to claim 1 can be found, for example, in paragraph [0006] of the specification.

The Examiner has required restriction to one of the following allegedly distinct inventions:

- I. Claims 1-28, drawn to an immunogenic composition;
- II. Claim 29, drawn to a method of delivering a therapeutic amount of an autigen;
- III. Claim 30, drawn to a method of treating a host having a pathogenic organism infection or tumor;
- IV. Claim 31, drawn to a method of immunizing a host animal against a tumor or infection by a pathogenic organism;
- V. Claims 32-39, drawn to a method of stimulating an immune response in a host animal;
- VI. Claims 40-74, drawn to an immunogenic composition;
- VII. Claim 75, drawn to a method of delivering a therapeutic amount of an antigen;
- VIII. Claim 76, drawn to a method of treating a host having a pathogenic organism infection or tumor;
- IX. Claim 77, drawn to a method of immunizing a host animal against a tumor or infection by a pathogenic organism;
- X. Claims 78-85, drawn to a method of stimulating an immune response in a host animal

Applicants elect the Group I claims, Claims 1-28, without traverse, for initial prosecution on the merits.

Pursuant to 35 U.S.C. 121, election of a single disclosed species of antigens and phospholipid compounds for prosecution on the merits is also required. Applicants hereby elect meningitis B as the antigen and the phospholipid of claim 9 as the phospholipid compound for prosecution on the merits. Claims 1, 3-16 and 18-28 are readable thereon.

Serial No.: 10/748,117

Should the Examiner be of the view that an interview would expedite consideration of the application, request is made that the Examiner telephone the Applicants' attorney at (703) 433-0510 in order that any outstanding issues be resolved.

Attorney for Applicant
Mayer & Williams, PC
251 North Avenue West, 2nd Floor
Westfield, NJ 07090

Tel.: 703-433-0510 Fax: 703-433-2362

Please continue to direct all correspondence to:
Novartis Vaccines and Diagnostics Inc.
Corporate Intellectual Property R338
P.O. Box 8097
Emeryville, CA 94662-8097

Respectfully submitted,

David B. Bonham Registration No. 34,297

I hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office on April 16, 2607 via facsimile to: 571-273-8300.

David B. Bonham

(Printed Name of Person Mailing Correspondence)

(Signature)